by British Medical Journal New drugs are often used not only for one disease (first approved indication) but also for other diseases (supplemental indications). But a study published by The BMJ finds that less than half of approved first indications for new drugs in the U.S. and Europe between 2011 and 2020 add substantial therapeutic value over existing...
